iTeos Therapeutics, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Revenue:
License and collaboration revenue
Total revenue
Operating expenses:
Research and development expenses
General and administrative expenses
Total operating expenses
Loss from operations
Other income and expense:
Grant income
Research and development tax credits
Fair value adjustment for preferred stock tranche rights liability and anti-dilution warrants liability
Fair value adjustment for preferred stock tranche rights liability
Interest income
Other income, net
Loss before income tax expense
Income tax expense
Net loss
Cumulative dividends on Series A Preferred Stock
Accretion of redeemable convertible preferred stock to redemption value
Series A Preferred Stock
Total accretion of redeemable convertible preferred stock to redemption value

Foreign currency translation adjustments
Unrealized gain related to available-for-sale debt securities
Comprehensive loss
Net loss attributable to common stockholders
Basic and diluted net loss per common share
Weighted-average common shares outstanding—basic and diluted
Basic net loss per common share
Diluted net loss per common share
Weighted-average common shares outstanding - basic
Weighted-average common shares outstanding - diluted

Comments